Literature DB >> 8472191

Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols.

J Birnbaum1, D Charpin, D Vervloet.   

Abstract

We compared 284 sting-allergic patients treated with either a 4 day (group 1), 6 hr (group 2) or 210 min (group 3) rapid venom immunotherapy (RVIT) protocol using honey bee (HB) or yellow jacket (YJ) venom at cumulative doses of 527.6 micrograms, 226.6 micrograms and 101.1 micrograms respectively. The 4 day protocol involved four times as many injections as the 210 min protocol and twice as many as the 6 hr protocol. Desensitization was conducted in a hospital providing full emergency resuscitation facilities. In group 1, 1 x 100 micrograms boosters were given on days 7, 10, 15 and 45 and, in groups 2 and 3, 2 x 50 micrograms boosters were given on day 15 and 1 x 100 micrograms on day 45. The patients in the three groups were comparable with regard to clinical characteristics and immunological reactivity determined by skin tests. All patients had large local reactions. Systemic reactions (SR) occurred in 28.2% of patients in group 1, 28.6% in group 2 and 6.9% in group 3. The mean total cumulative venom dose (s.e.m.) for occurrence of SR was 123.75 (+/- 24.2) in group 1, 183.27 (+/- 28.5) in group 2, and 36.43 (+/- 9.3) in group 3. HB led to more systemic reactions than YJ venom. The rate of SR decreased when the cumulative venom dose was reduced during RVIT. The median dose was 137.6 micrograms in group 1, 226.6 micrograms in group 2, and 21.1 micrograms in group 3. No systemic reactions were observed after the booster injections. The results of this study suggest that short RVIT protocols with low cumulative doses carry a lesser risk of SR.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8472191     DOI: 10.1111/j.1365-2222.1993.tb00886.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  19 in total

1.  Insect sting allergy. A study from 1980 to 2003 of patients who started treatment with venom immunotherapy between 1980 and 1998.

Authors:  Rolf Haye; Liv Kari Døsen
Journal:  Clin Mol Allergy       Date:  2005-08-19

2.  The local and systemic side-effects of venom and inhaled-allergen subcutaneous immunotherapy.

Authors:  Katja Adamic; Mihaela Zidarn; Nissera Bajrovic; Renato Erzen; Peter Kopac; Ema Music
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

Review 3.  Minimising the risks of allergen-specific injection immunotherapy.

Authors:  H J Malling
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

Review 4.  Clinical immunology review series: an approach to desensitization.

Authors:  M T Krishna; A P Huissoon
Journal:  Clin Exp Immunol       Date:  2010-12-22       Impact factor: 4.330

5.  Venom immunotherapy modulates interleukin-4 and interferon-gamma messenger RNA expression of peripheral T lymphocytes.

Authors:  H Akoum; A Tsicopoulos; H Vorng; B Wallaert; J P Dessaint; M Joseph; Q Hamid; A B Tonnel
Journal:  Immunology       Date:  1996-04       Impact factor: 7.397

Review 6.  Insect sting anaphylaxis.

Authors:  David B K Golden
Journal:  Immunol Allergy Clin North Am       Date:  2007-05       Impact factor: 3.479

Review 7.  [Specific immunotherapy. Hyposensitization with allergens].

Authors:  B Wedi; A Kapp
Journal:  Hautarzt       Date:  2004-04       Impact factor: 0.751

8.  Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro.

Authors:  C A Akdis; M Akdis; T Blesken; D Wymann; S S Alkan; U Müller; K Blaser
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

9.  Role of interleukin 10 in specific immunotherapy.

Authors:  C A Akdis; T Blesken; M Akdis; B Wüthrich; K Blaser
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

10.  Management of insect sting hypersensitivity: an update.

Authors:  Robert D Pesek; Richard F Lockey
Journal:  Allergy Asthma Immunol Res       Date:  2013-02-25       Impact factor: 5.764

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.